Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Clariant    CLN   CH0012142631

CLARIANT (CLN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Clariant : Launches Amide/Amine-Free Anti-Static Concentrate for...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/26/2017 | 07:10am CEST
  • MEVOPUR® anti-stat tested to new stringent regulations
  • Helps reduce risk and limitations of current technology
  • Maintains anti-static performance even at low humidity levels

Muttenz, September 26, 2017 - Clariant, a world leader in specialty chemicals, announces a new amide/amine-free anti-static masterbatch concentrate for polyethylene films used in pharmaceutical production. The new anti-stat, known under grade name MEVOPUR PEAM 176045, will be introduced at CPhI Worldwide, being held 24 - 26 October 2017 at Messe Frankfurt. Clariant is exhibiting on Stand 42L20.

The introduction is timely due to the changes in industry standards which, by 2020, will limit the acceptability of many of the currently used films that contain amide- and amine-based anti-stats, says Stephen Duckworth, Clariant's Head of Global Segment Medical and Pharmaceutical. For the first time, plastics used in pharma manufacturing, including anti-static films, will need to comply with the same standards as plastics packaging used for finished pharmaceuticals.

'Anti-static additives are routinely incorporated in the polyethylene 'clean-room films' that line containers and dispensers for active pharmaceutical ingredients (APIs), and in the tubes used to transfer powdered and liquid API during drug production. They are important because the anti-static properties help to reduce the risk of dangerous conditions like explosions,' he explained.

The new additive masterbatch concentrate is part of MEVOPUR, the brand of 'Controlled, Consistent and Compliant' products for plastics applications in the medical and pharmaceutical industries.

When incorporated into PE films Clariant's new anti-static provides very good static-dissipating performance and a competitive cost profile relative to alternatives. In addition, it has already been tested to the stricter new United States Pharmacopeia (USP) pharmaceutical standard for pharmaceutical-contacting plastics, which are scheduled to come into force in 2020. The new standard -- USP 'Plastic Components and Systems Used in the Manufacturing of Drug Products' -- will, for the first time, apply the same risk-based assessment of materials. Plastic components and single-use containers are increasingly used in manufacturing processes, particularly biological manufacturing processes. Despite their advantages, these plastic assemblies elicit concerns about chemical compounds that may leach or migrate into finished products and impact product quality or safety.

Historically, these anti-static films have predominantly relied on 'migrating' ethoxylated amine/amide-based anti-stats that had a degree of compliance to regulations for food contacting materials. Risk assessments that define migration limits applying to these additives cut allowable addition rates for amide- and amine-based additives to levels below of what is required for effective anti-static performance. This, in addition to the need to test at lower humidity levels (e.g.: , class VI. European Pharmacopeia and USP 661.1. This data, along with a ISO13485-based manufacturing/quality process, full change-control procedures, and documentation such as Drug Master File, help support the risk-management process of medical device producers. MEVOPUR 'Controlled, Consistent and Compliant' color and additive masterbatch concentrates and fully compounded plastics help manufacturers in the medical and pharmaceutical sectors control and minimize risk, while responding quickly to changing industry standards.

Besides the presence of Healthcare Polymer Solutions at CPhI 2017 please join also the experts from Clariant's Business Unit Industrial & Consumer Specialties in meeting room 'Inspiration 1' in hall 10.2 to discuss and learn about Polyglykol and the Macrogol range.

MEVOPUR® IS A TRADEMARK OF CLARIANT REGISTERED IN MANY COUNTRIES.

Clariant AG published this content on 26 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 September 2017 05:09:08 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLARIANT
12:24pCLARIANT : Stabilizer Jv Breaks Ground for New Plant in China
AQ
06/22CLARIANT : Opens Two New Facilities in China for Additive Production
AQ
06/21CLARIANT : breaks ground on joint venture production site in Cangzhou, China
PU
06/20CLARIANT : inaugurates new Additives production facilities in China
PU
06/18METAL DEACTIVATOR MARKET TO BE WORTH : Some of the major players in the global M..
AQ
06/14CLARIANT : supports China's auto industry in critical weight reduction & safety,..
PU
06/12CLARIANT : Catalysts collaborates with Hydrogenious Technologies in breakthrough..
PU
06/07CLARIANT : launches Playing with Beauty!, an innovative formulation concept for ..
PU
06/07CLARIANT : completes REACH registrations
PU
06/06CLARIANT : Deepak Parikh to join American Chemistry Council Board of Directors
PU
More news
News from SeekingAlpha
06/08Clariant (CLZNY) Presents At Credit Suisse 2018 Global Chemicals And Agricult.. 
04/25Clariant (CLZNF) Q1 2018 Results - Earnings Call Transcript 
04/25Clariant beats by CHF 3.4M on EBITDA, beats on revenue 
04/25Clariant AG 2018 Q1 - Results - Earnings Call Slides 
02/23Tracking Alex Roepers' Atlantic Investment Management Portfolio - Q4 2017 Upd.. 
Financials ( CHF)
Sales 2018 6 717 M
EBIT 2018 731 M
Net income 2018 429 M
Debt 2018 1 400 M
Yield 2018 2,27%
P/E ratio 2018 18,72
P/E ratio 2019 16,71
EV / Sales 2018 1,39x
EV / Sales 2019 1,31x
Capitalization 7 943 M
Chart CLARIANT
Duration : Period :
Clariant Technical Analysis Chart | CLN | CH0012142631 | 4-Traders
Technical analysis trends CLARIANT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 25,8  CHF
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
Hariolf Kottmann Chief Executive Officer & Executive Director
Rudolf Wehrli Chairman
Patrick Jany Chief Financial Officer
Peter Chen Non-Executive Director
Carlo G. Soave Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CLARIANT-13.21%8 033
ECOLAB3.50%40 067
SIKA AG0.00%20 823
SYMRISE5.22%11 400
JOHNSON MATTHEY PLC20.00%9 472
INDORAMA VENTURES PCL--.--%9 354